

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	<del>ZDB will be removed from STN</del>
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 23	Sep 03	JAPIO has been reloaded and enhanced
NEWS 24	Sep 16	Experimental properties added to the REGISTRY file
NEWS 25	Sep 16	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 27	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS EXPRESS		October 14 CURRENT WINDOWS VERSION IS V6.01, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 16:49:30 ON 17 OCT 2002

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:49:42 ON 17 OCT 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 OCT 2002 HIGHEST RN 462058-01-1  
DICTIONARY FILE UPDATES: 16 OCT 2002 HIGHEST RN 462058-01-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STN Note 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

Uploading 29839289.str

L1 STRUCTURE UPLOADED


=> d l1

L1 HAS NO ANSWERS

L1 STR

Patel

<10/17/2002>



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 16:50:08 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS  
SEARCH TIME: 00.00.01

1 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 3 TO 163  
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 16:50:16 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 12 TO ITERATE

100.0% PROCESSED 12 ITERATIONS  
SEARCH TIME: 00.00.02

1 ANSWERS

L3 1 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
140.28	140.49

FILE 'CAPLUS' ENTERED AT 16:50:24 ON 17 OCT 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

Patel

<10/17/2002>

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Oct 2002 VOL 137 ISS 16  
FILE LAST UPDATED: 16 Oct 2002 (20021016/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l1

---

#### REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...  
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 16:50:36 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS 1 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 3 TO 163  
PROJECTED ANSWERS: 1 TO 80

L4 1 SEA SSS SAM L1

L5 5 L4

=> d f bib hitstr abs total  
'F' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB  
ALL ----- BIB, AB, IND, RE  
APPS ----- AI, PRAI  
BIB ----- AN, plus Bibliographic Data and PI table (default)  
CAN ----- List of CA abstract numbers without answer numbers  
CBIB ----- AN, plus Compressed Bibliographic Data

DALL ----- ALL, delimited (end of each field identified)  
 DMAX ----- MAX, delimited for post-processing  
 FAM ----- AN, PI and PRAI in table, plus Patent Family data  
 FBIB ----- AN, BIB, plus Patent FAM  
 IND ----- Indexing data  
 IPC ----- International Patent Classifications  
 MAX ----- ALL, plus Patent FAM, RE  
 PATS ----- PI, SO  
 SAM ----- CC, SX, TI, ST, IT  
 SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;  
 SCAN must be entered on the same line as the DISPLAY,  
 e.g., D SCAN or DISPLAY SCAN)  
 STD ----- BIB, IPC, and NCL  
  
 IABS ----- ABS, indented with text labels  
 IALL ----- ALL, indented with text labels  
 IBIB ----- BIB, indented with text labels  
 IMAX ----- MAX, indented with text labels  
 ISTD ----- STD, indented with text labels  


---

 OBIB ----- AN, plus Bibliographic Data (original)  
 OIBIB ----- OBIB, indented with text labels  
  
 SBIB ----- BIB, no citations  
 SIBIB ----- IBIB, no citations  
  
 HIT ----- Fields containing hit terms  
 HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)  
 containing hit terms  
 HITRN ----- HIT RN and its text modification  
 HITSTR ----- HIT RN, its text modification, its CA index name, and  
 its structure diagram  
 HITSEQ ----- HIT RN, its text modification, its CA index name, its  
 structure diagram, plus NTE and SEQ fields  
 FHITSTR ----- First HIT RN, its text modification, its CA index name, and  
 its structure diagram  
 FHITSEQ ----- First HIT RN, its text modification, its CA index name, its  
 structure diagram, plus NTE and SEQ fields  
 KWIC ----- Hit term plus 20 words on either side  
 OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.  
 ENTER DISPLAY FORMAT (BIB):bib

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2002 ACS

AN 2002:51464 CAPLUS  
 DN 136:112673  
 TI Methods using a purine derivative, pyrimidine derivative, or tetrahydroindolone derivative for treatment of disease-induced peripheral neuropathy and related conditions  
 IN Diamond, Jack; Glasky, Alvin J.  
 PA Neotherapeutics, Inc., USA  
 SO PCT Int. Appl., 69 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004452	A2	20020117	WO 2001-US21526	20010706
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
	AU 2001071908	A5	20020121	AU 2001-71908	20010706
	US 2002055506	A1	20020509	US 2001-900844	20010706
	US 2002061899	A1	20020523	US 2001-899901	20010706
PRAI	US 2000-216844P	P	20000707		
	WO 2001-US21526	W	20010706		
OS	MARPAT 136:112673				

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2002 ACS  
 AN 2002:51463 CAPLUS  
 DN 136:112672  
 TI Methods using a purine derivative, pyrimidine derivative, or tetrahydroindolone derivative for stimulation of synthesis of synaptophysin in the central nervous system  
 IN Glasky, Michelle; Lahiri, Debomoy K.; Farlow, Martin R.  
 PA Neotherapeutics, Inc., USA  
 SO PCT Int. Appl., 59 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004451	A2	20020117	WO 2001-US21385	20010706
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,	

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 US 2002040032 A1 20020404 US 2001-899478 20010705  
 AU 2001073218 A5 20020121 AU 2001-73218 20010706  
 PRAI US 2000-216808P P 20000707  
 WO 2001-US21385 W 20010706  
 OS MARPAT 136:112672

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2002 ACS  
 AN 2002:51462 CAPLUS  
 DN 136:112671  
 TI Methods using a purine derivative, pyrimidine derivative, or  
 tetrahydroindolone derivative for prevention of accumulation of amyloid  
 .beta. peptide in the central nervous system  
 IN Glasky, Michelle; Lahiri, Debomoy K.; Farlow, Martin R.  
 PA Neotherapeutics, Inc., USA  
 SO PCT Int. Appl., 56 pp.  
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004450	A2	20020117	WO 2001-US21384	20010706
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				
	HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				
	LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				
	SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,				
	YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002040031	A1	20020404	US 2001-899611	20010705
	AU 2001073217	A5	20020121	AU 2001-73217	20010706
PRAI	US 2000-216845P	P	20000707		
	WO 2001-US21384	W	20010706		
OS	MARPAT 136:112671				

L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2002 ACS  
 AN 2002:51461 CAPLUS  
 DN 136:112691  
 TI Methods using a purine derivative, a pyrimidine derivative or a  
 tetrahydroindolone derivative for treatment of conditions affected by  
 activity of multidrug transporters  
 IN Taylor, Eve M.  
 PA Neotherapeutics, Inc., USA  
 SO PCT Int. Appl., 70 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2002004449 A2 20020117 WO 2001-US21383 20010706  
 WO 2002004449 A3 20020613  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,  
 YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 US 2002128264 A1 20020912 US 2001-900297 20010706  
 PRAI US 2000-216616P P 20000707  
 OS MARPAT 136:112691

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2002 ACS  
 AN 2002:51460 CAPLUS  
 DN 136:112670

TI ~~Methods using purine derivatives, pyrimidine derivatives, and~~  
~~tetrahydroindolone derivatives for treatment of drug-induced peripheral~~  
~~neuropathy and related conditions~~

IN Diamond, Jack; Glasky, Alvin J.

PA Neotherapeutics, Inc., USA

SO PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004448	A2	20020117	WO 2001-US21373	20010706
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001073212	A5	20020121	AU 2001-73212	20010706
	US 2002055506	A1	20020509	US 2001-900844	20010706
	US 2002061899	A1	20020523	US 2001-899901	20010706
PRAI	US 2000-216844P	P	20000707		
	WO 2001-US21373	W	20010706		
OS	MARPAT 136:112670				

=> log y

COST IN U.S. DOLLARS

SINCE FILE TOTAL  
ENTRY SESSION  
5.57 146.84

FULL ESTIMATED COST

STN INTERNATIONAL LOGOFF AT 16:51:42 ON 17 OCT 2002

Patel

<10/17/2002>



CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004452	A2	20020117	WO 2001-US21526	20010706
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2001071908	A5	20020121	US 2000-216844PP	20000707
				AU 2001-71908	20010706
				US 2000-216844PP	20000707
	US 2002055506	A1	20020509	WO 2001-US21526W	20010706
				US 2001-900844	20010706
	US 2002061899	A1	20020523	US 2000-216844PP	20000707
				US 2001-899901	20010706
				US 2000-216844PP	20000707

## PATENT FAMILY INFORMATION:

FAN 2002:51460

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004448	A2	20020117	WO 2001-US21373	20010706
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2001073212	A5	20020121	US 2000-216844PP	20000707
				AU 2001-73212	20010706
				US 2000-216844PP	20000707
	US 2002055506	A1	20020509	WO 2001-US21373W	20010706
				US 2001-900844	20010706
	US 2002061899	A1	20020523	US 2000-216844PP	20000707
				US 2001-899901	20010706
				US 2000-216844PP	20000707


OS MARPAT 136:112673

IT 389799-42-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(purine derivs., pyrimidine derivs., and tetrahydroindolone derivs.  
 for treatment of disease-induced peripheral neuropathy and related conditions)

RN 389799-42-2 CAPLUS  
 CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



AB A method of treating disease-induced peripheral neuropathy comprises administering to a patient with disease-induced peripheral neuropathy an effective quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. The compd. can induce peripheral nerve sprouting through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The disease-induced peripheral neuropathy can be diabetic neuropathy or disease-induced peripheral neuropathy with another basis.

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2002 ACS

AN 2002:51463 CAPLUS

DN 136:112672

TI Methods using a purine derivative, pyrimidine derivative, or tetrahydroindolone derivative for stimulation of synthesis of synaptophysin in the central nervous system

IN Glasky, Michelle; Lahiri, Debomoy K.; Farlow, Martin R.

PA Neotherapeutics, Inc., USA

SO PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2002004451	A2	20020117	WO 2001-US21385	20010706	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	US 2002040032	A1	20020404	US 2000-216808PP	20000707	
				US 2001-899478	20010705	
				US 2000-216808PP	20000707	
	AU 2001073218	A5	20020121	AU 2001-73218	20010706	

US 2000-216808PP 20000707  
WO 2001-US21385W 20010706

OS MARPAT 136:112672  
 IT **389799-42-2**  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (purine deriv., pyrimidine deriv., or tetrahydroindolone deriv. for stimulation of synthesis of synaptophysin in CNS)  
 RN 389799-42-2 CAPLUS  
 CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



AB A method of increasing the synthesis and/or secretion of synaptophysin comprises administering to a patient with a neurol. disease or a patient at risk of developing a neurol. disease an effective quantity of a purine deriv. of analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. The neurol. disease can be a neurodegenerative disease such as Alzheimer's disease or a neurodevelopmental disorder such as Down's syndrome. Typically, the compd. can pass through the blood-brain barrier. A particularly preferred purine deriv. is N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide.

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2002 ACS  
 AN 2002:51462 CAPLUS  
 DN 136:112671

TI Methods using a purine derivative, pyrimidine derivative, or tetrahydroindolone derivative for prevention of accumulation of amyloid .beta. peptide in the central nervous system

IN Glasky, Michelle; Lahiri, Debomoy K.; Farlow, Martin R.

PA Neotherapeutics, Inc., USA

SO PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002004450	A2	20020117	WO 2001-US21384	20010706
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				

SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,  
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002040031 A1 20020404 US 2000-216845PP 20000707  
US 2001-899611 20010705  
US 2000-216845PP 20000707  
AU 2001073217 A5 20020121 AU 2001-73217 20010706  
US 2000-216845PP 20000707  
WO 2001-US21384W 20010706

OS MARPAT 136:112671


IT **389799-42-2**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(purine deriv., pyrimidine deriv., or tetrahydroindolone deriv. for  
prevention of accumulation of amyloid .beta. peptide in CNS)

RN 389799-42-2 CAPLUS

CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-  
yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



AB A method of either inhibiting the formation of A.beta. or stimulating the  
formation of sAPP comprises administering to a patient with a neurol.  
disease or a patient at risk of developing a neurol. disease an effective  
quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or  
analog, or a pyrimidine deriv. or analog. If the compd. is a purine  
deriv., the purine moiety can be guanine or hypoxanthine. The neurol.  
disease can be a neurodegenerative disease such as Alzheimer's disease or  
a neurodevelopmental disorder such as Down's syndrome. Typically, the  
compd. can pass through the blood-brain barrier. A particularly  
preferred  
purine deriv. is N-4- carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide.

L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2002 ACS

AN 2002:51461 CAPLUS

DN 136:112691

TI Methods using a purine derivative, a pyrimidine derivative or a  
tetrahydroindolone derivative for treatment of conditions affected by  
activity of multidrug transporters

IN Taylor, Eve M.

PA Neotherapeutics, Inc., USA

SO PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004449	A2	20020117	WO 2001-US21383	20010706
	WO 2002004449	A3	20020613		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 2002128264	A1	20020912	US 2000-216616PP	20000707
				US 2001-900297	20010706
				US 2000-216616PP	20000707

OS MARPAT 136:112691


IT ~~389799-42-2~~

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (purine deriv., pyrimidine deriv. or tetrahydroindolone deriv. for treatment of conditions affected by activity of multidrug

transporters)

RN 389799-42-2 CAPLUS

CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



AB One aspect of the invention is a method of treating a condition or disease

assocd. with the activity of a multidrug transporter protein comprising administering to a mammal with a condition or disease assocd. with the activity of a multidrug transporter protein an effective quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine

moiety can be guanine or hypoxanthine. A particularly preferred bifunctional purine deriv. is N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide. The methods of the invention can be used to treat cancer,

a microbial or parasitic infection, HIV, infection, or a condition assocd.

with inflammation, e.g. asthma or rheumatic disease.

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2002 ACS

Patel

&lt;10/17/2002&gt;

AN 2002:51460 CAPLUS  
 DN 136:112670  
 TI Methods using purine derivatives, pyrimidine derivatives, and  
 tetrahydroindolone derivatives for treatment of drug-induced peripheral  
 neuropathy and related conditions  
 IN Diamond, Jack; Glasky, Alvin J.  
 PA Neotherapeutics, Inc., USA  
 SO PCT Int. Appl., 66 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002004448	A2	20020117	WO 2001-US21373	20010706
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG US 2000-216844PP 20000707 AU 2001073212 A5 20020121 AU 2001-73212 20010706 US 2000-216844PP 20000707 WO 2001-US21373W 20010706 US 2002055506 A1 20020509 US 2001-900844 20010706 US 2000-216844PP 20000707 US 2002061899 A1 20020523 US 2001-899901 20010706 US 2000-216844PP 20000707				

## PATENT FAMILY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002004452	A2	20020117	WO 2001-US21526	20010706
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG US 2000-216844PP 20000707 AU 2001071908 A5 20020121 AU 2001-71908 20010706 US 2000-216844PP 20000707 WO 2001-US21526W 20010706 US 2002055506 A1 20020509 US 2001-900844 20010706 US 2000-216844PP 20000707 US 2002061899 A1 20020523 US 2001-899901 20010706 US 2000-216844PP 20000707				

OS MARPAT 136:112670

IT 389799-42-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(purine derivs., pyrimidine derivs., and tetrahydroindolone derivs.

for

treatment of drug-induced peripheral neuropathy and related conditions)

RN 389799-42-2 CAPLUS

CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



AB A method of treating drug-induced peripheral neuropathy comprises administering to a patient with drug-induced peripheral neuropathy an effective quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. The compd. can induce peripheral nerve sprouting through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The drug-induced peripheral neuropathy can be drug-induced peripheral neuropathy assocd. with the administration of oncolytic drugs, such as a vinca alkaloid, cisplatin, paclitaxel, suramin, altretamine, carboplatin, chlorambucil, cytarabine, dacarbazine, docetaxel, etoposide, fludarabine, ifosfamide with mesna, tamoxifen, teniposide, or thioguanine. The methods of the invention are particularly useful in treating peripheral neuropathy assocd. with the administration of vincristine, paclitaxel, or cisplatin.

=&gt; log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
33.85	175.50

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-3.10	-3.10

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 16:42:17 ON 17 OCT 2002

